Synapse - Works

Results (3351)

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers

Meeting Abstract

Johnson, M. L.; Dy, G. K.; Mamdani, H.; Dowlati, A.; Schoenfeld, A. J.; Pacheco, J. M.; Sanborn, R. E.; Menon, S. P.; Santiago, L.; Yaron, Y.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD

Meeting Abstract

Janne, P. A.; Ramalingam, S. S.; Yang, J. C. H.; Riely, G. J.; Bunn, V.; Jin, S.; Zhou, C.; Camidge, D. R.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma

Meeting Abstract

Ip, A.; Gutierrez, M.; Warren, M. E.; Pfister, D. G.; Brady, O.; Shen, R. L.; Riely, G. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mechanisms of acquired resistance to TRK inhibitors

Meeting Abstract

Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P

Meeting Abstract

Grant, M. J.; Aredo, J. V.; Starrett, J.; Wurtz, A.; Piotrowska, Z.; Piper-Vallillo, A.; Yu, H. A.; Falcon, C.; Patil, T.; Nguyen, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs)

Meeting Abstract

Gainor, J. F.; Ravi, A.; Awad, M. M.; Holton, M.; Arniella, M.; Stewart, C.; Freeman, S.; Leshchiner, I.; Chow, A.; Henick, B. S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399

Meeting Abstract

Gentzler, R. D.; Piekarz, R.; Villaruz, L. C.; Rhee, J. C.; Lai, W. C. V.; Horton, B.; Mock, J.; Hanley, M.; Rudek, M. A.; Phelps, M. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma-A phase 3 randomized trial

Meeting Abstract

Forde, P. M.; Nowak, A. K.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K. J.; Yip, S.; Cook, A.; Lesterhuis, W. J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer

Meeting Abstract

Elkrief, A.; Machado Alessi, J. V.; Ricciuti, B.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Chaft, J. E.; Rudin, C. M.; Riely, G. J.; Kris, M. G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

Meeting Abstract

Drilon, A. E.; Hong, D. S.; Van Tilburg, C. M.; Doz, F.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; McDermott, R. S.; Zwaan, C. M.; Norenberg, R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save